(Q42911266)

11 November 2017

Impact of anti-drug antibodies in preclinical pharmacokinetic assessment (English)

1 reference

11 November 2017

1 reference

1 reference

Theingi M Thway

1

1 reference

11 November 2017

Ivan Magana

2

1 reference

11 November 2017

Ami Bautista

3

1 reference

11 November 2017

Vibha Jawa

4

1 reference

11 November 2017

Wen Gu

5

1 reference

11 November 2017

Mark Ma

6

1 reference

11 November 2017

language of work or name

English

0 references

publication date

8 May 2013

1 reference

11 November 2017

1 reference

11 November 2017

15

1 reference

11 November 2017

3

1 reference

11 November 2017

856-863

1 reference

https://scigraph.springernature.com/pub.10.1208/s12248-013-9484-4

11 November 2017

0 references

cites work

Universal immunoassay applied during early development of large molecules to understand impact of immunogenicity on biotherapeutic exposure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3691432

Immunogenicity assessment in non-clinical studies

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3691432

Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3691432

Model-based strategy for bioanalytical method comparison: measurement of a soluble ligand as a biomarker

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3691432

Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3691432

Specificity and selectivity evaluations of ligand binding assay of protein therapeutics against concomitant drugs and related endogenous proteins

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3691432

Paradigm of combination biologics: analytical challenges related to pharmacokinetic assays and interpretation of pharmacokinetic and immunogenicity results

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3691432

Experimental and statistical approaches in method cross-validation to support pharmacokinetic decisions

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3691432

Understanding and mitigating impact of immunogenicity on pharmacokinetic assays

16 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23653044

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

International Conference on Harmonisation; addendum to International Conference on Harmonisation Guidance on S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals; availability. Notice

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23653044

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Implementation of a universal analytical method in early-stage development of human antibody therapeutics: application to pharmacokinetic assessment for candidate selection

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23653044

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1208/S12248-013-9484-4

1 reference

Dimensions Publication ID

11 November 2017

0 references

1 reference

11 November 2017

PubMed publication ID

23653044

1 reference